share_log

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5：募资说明书
美股sec公告 ·  06/27 13:08
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of 30,769,230 shares of its Class A common stock at a public offering price of $6.50 per share. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is detailed in the prospectus supplement dated June 26, 2024. The shares are listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The last reported sale price of Recursion's Class A Common Stock on Nasdaq was $8.76 per share as of June 26, 2024. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, who have the option to purchase an additional 4,615,384 shares. The offering is expected to close on or about June 28, 2024. The net proceeds from the offering, estimated at approximately $188.9 million before expenses, are intended for the advancement of Recursion's preclinical and clinical programs, platform technologies, and for general corporate purposes, including potential strategic investments and acquisitions.
Recursion Pharmaceuticals, Inc.（Recursion）宣布以每股6.50美元的公开发行价格公开发行30,769,230股A类普通股。该发行根据《证券交易委员会规则424(b)(5)》在证券交易委员会(SEC)备案，并在于2024年6月26日的招股说明书中详细说明。这些股票在纳斯达克全球精选市场上以“RXRX”为符号挂牌交易。据2024年6月26日纳斯达克成交价显示，Recursion的A类普通股上一报告销售价格为8.76美元每股。发行商为高盛、摩根大通和艾伦公司有限责任公司，他们有权购买另外4,615,384股股票。发行预计将于2024年6月28日或前后结束。预计净收益为大约1.89亿美元，净扣除费用后将用于推进Recursion的临床前和临床计划、平台技术以及一般企业用途，包括可能的战略投资和收购。
Recursion Pharmaceuticals, Inc.（Recursion）宣布以每股6.50美元的公开发行价格公开发行30,769,230股A类普通股。该发行根据《证券交易委员会规则424(b)(5)》在证券交易委员会(SEC)备案，并在于2024年6月26日的招股说明书中详细说明。这些股票在纳斯达克全球精选市场上以“RXRX”为符号挂牌交易。据2024年6月26日纳斯达克成交价显示，Recursion的A类普通股上一报告销售价格为8.76美元每股。发行商为高盛、摩根大通和艾伦公司有限责任公司，他们有权购买另外4,615,384股股票。发行预计将于2024年6月28日或前后结束。预计净收益为大约1.89亿美元，净扣除费用后将用于推进Recursion的临床前和临床计划、平台技术以及一般企业用途，包括可能的战略投资和收购。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息